



OpenDEX

Looking for an affordable way to **screen billions of small molecules**? Explore our flexible OpenDEX offering.

Access the X-Chem DEL Small Molecule Discovery Engine Your Way

Immense opportunities are within reach. You may think access to state-of-the-art DNA-encoded library (DEL) screening is only for deep-pocketed big pharma. But at X-Chem, our mission is to deploy the power of DEL to benefit a diverse range of partners. For emerging pharma and biotech clients, we've created a partnership model that gives you access to our groundbreaking DEL screening platform under flexible terms.

You can investigate a hugely diverse range of molecules that hold enormous potential, with guidance from the world's top DEL experts. The X-Chem team pioneered DEL-driven drug discovery. We're excited to help find novel hits and leads to your target with unprecedented speed and clarity.

Enjoy the Full Power of DEL Affordably With an OpenDEX Partnership

High-quality libraries, experienced DEL operators and powerful statistical and computational approaches make up the X-Chem discovery engine and enable you to unlock exponential possibilities in your small molecule drug discovery. More flexible deal structures allow you to assess target tractability and identify hits for all types of biological targets on your own terms.

You will receive the full breadth of the DEL output and be able to apply your own knowledge to prioritize and focus your efforts on the most promising, novel and attractive compounds. OpenDEX libraries represent the latest DEL design concepts, with a focus on atom economy and developability.

Benefits of OpenDEX DNA-Encoded Library-Based Screening Offering

X-Chem's industry-leading screening resource with unrivaled productivity is your solution for rapidly building a drug discovery pipeline.

Advanced OpenDEX Library Set Used for Screens

- Progressive DEL design concepts
- Informed by many years of DEL performance
- Drug-like molecular properties
- Focused on developability
- Billions of compounds and growing
- Bundled for lower cost

continued on back >

COMPARISON OF X-CHEM PARTNERSHIP SOLUTIONS FOR COMPOUND SCREENING AND IDENTIFICATION

PartnerDEX

- › Full service customizable Discovery Partnership
- › Access to X-Chem's complete DEL library collection
- › Experienced program management and oversight
- › Exclusive license to confirmed hit compounds
- › Target based exclusivity for duration of your program

OpenDEX

- › Access to newest library designs and X-Chem's industry-leading DEL expertise
- › Flexible deal structure
- › No downstream financial obligations
- › In-depth DEL data deliverable

(Benefits of OpenDEX cont.)

Full Breadth of DEL Output

- › Get more than hits
- › Understand trends and groupings

Flexible Deal Structure

- › Transparent cost structure
- › No downstream financial obligations
- › Minimal commitment

Fast Chemistry Follow-Up

- › Save time
- › Only progress the compounds with the most promise

Add-on Services

- › Target protein QC
- › Compound synthesis
- › Hit testing
- › Follow-on hit-to-lead

Optional Hit-to-Lead and Lead Optimization Partnership

OpenDEX partners may also choose to work with X-Chem for hit-to-lead and lead optimization. Our team's expertise in medicinal and synthetic chemistry is unrivaled in the DEL space, and we have extensive experience in converting screening hits into clinical candidates. Because we are experts in the unique chemistry of the OpenDEX libraries, our partners can be confident that they will enjoy the most efficient and rapid chemistry follow-up possible. Where others might struggle to develop the appropriate schemes and source the requisite building blocks, X-Chem scientists are prepared on Day One to rapidly push OpenDEX outputs forward. After all, we made the libraries in the first place!

X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery.

Find Your Next Candidate With X-Chem

ABOUT X-CHEM

X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.